Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from SinoMab Bioscience Ltd. ( (HK:3681) ) is now available.
SinoMab BioScience has received approval from China’s National Medical Products Administration for an investigational new drug application to test SM17 in inflammatory bowel disease, expanding the molecule’s scope beyond atopic dermatitis. The company has completed a Phase I subcutaneous bridging study in healthy volunteers and plans to use the data to support further clinical development, including Phase II trials.
SM17 is a first‑in‑class humanized monoclonal antibody targeting the IL‑25 receptor to modulate Type 2 inflammatory responses, positioning it as a differentiated option for ulcerative colitis and potentially Crohn’s disease. SinoMab views the new IBD indication, alongside ongoing formulation work and an upcoming Phase II trial in atopic dermatitis, as a major clinical and commercial opportunity in a market where many patients do not respond durably to existing biologics.
The most recent analyst rating on (HK:3681) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a Hong Kong‑incorporated biopharmaceutical company focused on developing first‑in‑class monoclonal antibody therapies. The group’s pipeline targets immune‑mediated and inflammatory diseases, with a particular emphasis on Type 2 inflammation and conditions such as atopic dermatitis and inflammatory bowel disease in major global markets.
Average Trading Volume: 5,291,021
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.68B
See more data about 3681 stock on TipRanks’ Stock Analysis page.